Melphalan

Melphalan
Melphalan
Systematic (IUPAC) name
4-[bis(chloroethyl)amino]phenylalanine
Clinical data
Trade names Alkeran
AHFS/Drugs.com monograph
MedlinePlus a682220
Pregnancy cat.  ?
Legal status Prescription only
Routes Oral, intravenous
Pharmacokinetic data
Bioavailability 25% to 89%
Metabolism hydrolysis
Half-life 1.5 ± 0.8 hours
Excretion Renal, significantly metabolised
Identifiers
CAS number 148-82-3 YesY
ATC code L01AA03
PubChem CID 4053
DrugBank APRD00118
ChemSpider 405297 YesY
UNII Q41OR9510P YesY
KEGG D00369 YesY
ChEBI CHEBI:28876 N
ChEMBL CHEMBL852 YesY
Synonyms 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]-propanoic acid
Chemical data
Formula C13H18Cl2N2O2 
Mol. mass 305.2 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Melphalan hydrochloride (trade name Alkeran) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents.

An alkylating agent adds an alkyl group (CnH2n+1) to DNA. It attaches the alkyl group to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring.

Otherwise known as L-Phenylalanine Mustard, or L-PAM, melphalan is a phenylalanine derivative of mechlorethamine.

Contents

Uses

It is used to treat multiple myeloma[1] and ovarian cancer, and occasionally malignant melanoma.

The agent was first investigated as a possible drug for use in melanoma. It was not found to be effective, but has been found to be effective in the treatment of myeloma.

Administration

Oral or intravenous; dosing varies by purpose and route of administration as well as patient weight.

Melphalan Prescribing Information: Alkeran[2]

Melphalan Patient Information: MedlinePlus[3]

Melphalan Material Safety Data Sheet (MSDS): Sequoia Research Products[4]

Side effects

Common side effects include:

Less common side effects include:

  • Severe allergic reactions
  • Pulmonary fibrosis (scarring of lung tissue) including fatal outcomes (usually only with prolonged use)
  • Hair loss
  • Interstitial pneumonitis
  • Rash
  • Itching
  • Irreversible bone marrow failure due to melphalan not being withdrawn early enough.
  • Cardiac arrest.

References